Single DMT dose combined with therapy eases severe depression for months

A single intravenous dose of DMT—a powerful psychedelic compound—can produce rapid and lasting relief from treatment-resistant depression, according to a small clinical trial published in Nature Medicine.

The 34-person study found that when DMT was paired with psychotherapy, people with moderate to severe depression showed significant improvement in symptoms that persisted for three to six months after a single 25-minute experience. Some participants still reported benefits six months later.

"There is an immediate antidepressant effect that is significantly sustained over a three-month period," said Dr. David Erritzoe, the psychiatrist at Imperial College London who led the research. "And that's exciting because this is one session with a drug, embedded in psychological support."

Half the participants received a 21.5mg intravenous dose of DMT infused over 10 minutes. The other half received a placebo. All participants underwent psychotherapy and follow-up assessments. Those given DMT showed substantially greater improvement on standard depression measures than the placebo group.

How it works

DMT is the active compound in ayahuasca, a brew used in South American shamanic rituals. It produces intense, often mystical hallucinations that can last around 25 minutes—much shorter than psilocybin (magic mushrooms), which creates trips lasting a couple of hours.

Researchers believe psychedelics work by disrupting entrenched patterns of thinking. Erritzoe describes the mechanism as "shaking up the snow on a mountain and flattening the hills and valleys so people can easily find new routes." The drug appears to loosen rigid thought patterns, allowing psychotherapy to take root more effectively.

The shorter duration of DMT's effects could make it easier for clinics to administer compared to longer-acting psychedelics, though patients may need more intensive support during the intense experience itself.

This research builds on earlier positive trials with psilocybin for depression. If regulators approve psychedelics for treating depression—expected later this year in some jurisdictions—they'll likely be available initially through private clinics rather than the NHS.

That raises a question: how do you scale something this promising without letting commercial pressures compromise safety. The Feilding Commission, established last year, is working to establish guidelines for safe, ethical, and equitable rollout of psychedelic-assisted therapy. Their work will be crucial as these treatments move from research labs toward actual clinical availability.